SLRX vs. SNOA, CYTO, ATXI, NTBL, DRMA, ONCO, CMND, CNSP, SXTP, and AGRX
Should you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Sonoma Pharmaceuticals (SNOA), Altamira Therapeutics (CYTO), Avenue Therapeutics (ATXI), Notable Labs (NTBL), Dermata Therapeutics (DRMA), Onconetix (ONCO), Clearmind Medicine (CMND), CNS Pharmaceuticals (CNSP), 60 Degrees Pharmaceuticals (SXTP), and Agile Therapeutics (AGRX). These companies are all part of the "pharmaceutical preparations" industry.
Salarius Pharmaceuticals (NASDAQ:SLRX) and Sonoma Pharmaceuticals (NASDAQ:SNOA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.
Sonoma Pharmaceuticals received 190 more outperform votes than Salarius Pharmaceuticals when rated by MarketBeat users. Likewise, 67.50% of users gave Sonoma Pharmaceuticals an outperform vote while only 54.17% of users gave Salarius Pharmaceuticals an outperform vote.
Sonoma Pharmaceuticals has a consensus price target of $3.25, indicating a potential upside of 1,331.72%. Given Sonoma Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Sonoma Pharmaceuticals is more favorable than Salarius Pharmaceuticals.
In the previous week, Salarius Pharmaceuticals and Salarius Pharmaceuticals both had 1 articles in the media. Salarius Pharmaceuticals' average media sentiment score of 1.22 beat Sonoma Pharmaceuticals' score of 0.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the media.
Salarius Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Sonoma Pharmaceuticals has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.
11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. 3.5% of Salarius Pharmaceuticals shares are held by company insiders. Comparatively, 9.2% of Sonoma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Salarius Pharmaceuticals has a net margin of 0.00% compared to Sonoma Pharmaceuticals' net margin of -41.24%. Sonoma Pharmaceuticals' return on equity of -58.93% beat Salarius Pharmaceuticals' return on equity.
Sonoma Pharmaceuticals has higher revenue and earnings than Salarius Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Sonoma Pharmaceuticals beats Salarius Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Salarius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Salarius Pharmaceuticals Competitors List
Related Companies and Tools
